VVD-133214 + Pembrolizumab for Colorectal Cancer

This trial tests a new treatment combination for individuals with advanced colorectal cancer that remains untreated. It combines VVD-133214, a drug designed to block Werner helicase—a protein that aids cancer cell survival—with pembrolizumab, an immunotherapy that enhances the immune system's ability to attack cancer. The researchers aim to determine if this combination outperforms pembrolizumab alone. Individuals with advanced colorectal cancer and specific genetic changes (MSI or dMMR) who have not received prior treatment may be suitable candidates. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

Research has shown that VVD-133214, when combined with pembrolizumab, is generally safe and well-tolerated. Early studies indicate that VVD-133214 does not cause serious side effects and has shown promising results in early tests for MSI-high colorectal cancer, leading to significant tumor shrinkage.

Pembrolizumab, the other drug in this combination, is already approved for treating certain cancers and has a well-known safety record. Past studies revealed that fewer patients experienced severe side effects compared to those receiving traditional chemotherapy.

Researchers are excited about these treatments because VVD-133214, when combined with pembrolizumab, has the potential to enhance the immune response against colorectal cancer. Unlike standard treatments that often focus solely on chemotherapy, VVD-133214 may target specific pathways to boost the effectiveness of pembrolizumab, a well-known immunotherapy. This combination aims to improve patient outcomes by potentially increasing the body's ability to fight cancer cells more effectively. The study explores two different doses of VVD-133214, which could provide insights into optimizing treatment efficacy and safety.

Research has shown that using VVD-133214 with pembrolizumab may help treat advanced colorectal cancer, particularly in cases with specific genetic features called MSI and dMMR. In this trial, participants will receive either VVD-133214 combined with pembrolizumab or pembrolizumab alone. Studies have demonstrated that VVD-133214 blocks a protein essential for cancer cell growth, leading to significant tumor shrinkage in lab tests. Pembrolizumab, an approved treatment, extended the time patients lived without their cancer worsening to 16.5 months. The goal of combining these treatments is to enhance effectiveness while minimizing harm to healthy cells.¹⁶⁷⁸⁹